Evaluation of Multimodality Management of Adenoid Cystic Carcinoma of the Head and Neck
Authors:
- 7 July 2018
- journal article
- research article
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 71 (S1) , 628-632
Abstract
Adenoid cystic carcinoma is a relatively rare tumour arising from salivary glands of head and neck region. Surgery and radiotherapy form standard treatment modalities in the management of this tumor. In this analysis we present results of multimodality treatment in our cohort of patient. This retrospective analysis evaluated results of treatment in forty patients diagnosed with adenoid cystic carcinoma of the head and neck. Evaluation was done to identify prognostic factors affecting the disease free survival. A median disease free survival of 34 ± 2.42 (Median ± SE) versus 10 ± 5.45 months was seen in patients undergoing surgery followed by post operative radiotherapy versus radiotherapy alone (P = 0.01). A radiotherapy dose more than 60 Gy was associated with a better disease free survival compared with patients receiving less than 60 Gy (P = 0.01). Positive surgical margins and perineural invasion were associated with a poor treatment outcome (P = 0.02) Patients with c-kit positive status showed a poor local control rate (P = 0.05).Keywords
This publication has 18 references indexed in Scilit:
- Clinical prognostic factors of salivary adenoid cystic carcinoma: A single-center analysis of 61 patientsJournal of Cranio-Maxillofacial Surgery, 2017
- Adenoid cystic carcinoma of the head and neck: a retrospective multicenter studyActa Oto-Laryngologica, 2017
- Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14‐01)Cancer, 2017
- Adenoid cystic carcinoma of the head and neck – An updateOral Oncology, 2015
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KITJournal of Clinical Oncology, 2008
- Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: Prognostic features of recurrenceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Imatinib Mesylate Can Induce Objective Response in Progressing, Highly Expressing KIT Adenoid Cystic Carcinoma of the Salivary GlandsJournal of Clinical Oncology, 2005
- Role for Postoperative Radiation Therapy in Adenoid Cystic Carcinoma of the Head and NeckThe Laryngoscope, 2004
- Expression of KIT (CD117) in Neoplasms of the Head and Neck: An Ancillary Marker for Adenoid Cystic CarcinomaLaboratory Investigation, 2003
- Adenoid Cystic Carcinoma of the Head and NeckJAMA Otolaryngology–Head & Neck Surgery, 1999